Gilead Sciences, Inc. (GILD) Shares Bought by Mutual of Omaha Bank Wealth Management

Share on StockTwits

Mutual of Omaha Bank Wealth Management boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 9,628 shares of the biopharmaceutical company’s stock after acquiring an additional 275 shares during the period. Mutual of Omaha Bank Wealth Management’s holdings in Gilead Sciences were worth $602,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Advisors Preferred LLC purchased a new position in Gilead Sciences during the fourth quarter worth about $31,000. Legacy Financial Advisors Inc. boosted its stake in Gilead Sciences by 361.3% during the fourth quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 383 shares during the period. We Are One Seven LLC purchased a new position in Gilead Sciences during the fourth quarter worth about $37,000. Jackson Grant Investment Advisers Inc. boosted its stake in Gilead Sciences by 56.9% during the fourth quarter. Jackson Grant Investment Advisers Inc. now owns 717 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 260 shares during the period. Finally, Baldwin Brothers Inc. MA boosted its stake in Gilead Sciences by 47.2% during the fourth quarter. Baldwin Brothers Inc. MA now owns 808 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 259 shares during the period. Institutional investors own 80.03% of the company’s stock.

GILD stock opened at $67.59 on Monday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.29 and a current ratio of 3.36. Gilead Sciences, Inc. has a twelve month low of $60.32 and a twelve month high of $82.71. The company has a market cap of $87.44 billion, a price-to-earnings ratio of 10.99, a P/E/G ratio of 4.15 and a beta of 1.19.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing analysts’ consensus estimates of $1.70 by ($0.26). Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same period in the previous year, the business posted $1.78 EPS. The firm’s revenue for the quarter was down 2.6% compared to the same quarter last year. As a group, analysts predict that Gilead Sciences, Inc. will post 6.23 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Shareholders of record on Friday, March 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $2.52 dividend on an annualized basis and a yield of 3.73%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.57. Gilead Sciences’s dividend payout ratio (DPR) is presently 37.07%.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $71.20, for a total transaction of $3,560,000.00. Following the sale, the director now owns 2,877,762 shares of the company’s stock, valued at $204,896,654.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.16% of the stock is currently owned by company insiders.

GILD has been the topic of several analyst reports. ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Saturday, December 1st. Zacks Investment Research cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, January 23rd. Citigroup reaffirmed a “buy” rating and issued a $100.00 target price on shares of Gilead Sciences in a report on Tuesday, February 5th. Mizuho set a $94.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a report on Thursday, November 1st. Finally, CIBC raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 target price on the stock in a report on Thursday, January 3rd. Two analysts have rated the stock with a sell rating, nine have given a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $84.01.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/4161360/gilead-sciences-inc-gild-shares-bought-by-mutual-of-omaha-bank-wealth-management.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Recommended Story: How to invest in a bear market

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Cipher Capital LP Buys New Holdings in Fortune Brands Home & Security Inc
Cipher Capital LP Buys New Holdings in Fortune Brands Home & Security Inc
Nektar Therapeutics  Shares Sold by Gotham Asset Management LLC
Nektar Therapeutics Shares Sold by Gotham Asset Management LLC
Cipher Capital LP Takes $906,000 Position in New York Times Co
Cipher Capital LP Takes $906,000 Position in New York Times Co
Cipher Capital LP Invests $821,000 in Sensata Technologies Holding PLC  Stock
Cipher Capital LP Invests $821,000 in Sensata Technologies Holding PLC Stock
Capital Financial Planning LLC Buys New Position in NEWTEK Business Services Corp
Capital Financial Planning LLC Buys New Position in NEWTEK Business Services Corp
Genuine Parts  Position Lowered by Fmr LLC
Genuine Parts Position Lowered by Fmr LLC


© 2006-2019 Ticker Report